Lung Disease - Pipeline Review - H1 2014





Published: March 2014 | Pages: 55 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘Lung Disease - Pipeline Review, H1 2014’, provides an overview of the Lung Disease’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Lung Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Disease and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  The report provides a snapshot of the global therapeutic landscape of Lung Disease 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Lung Disease and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Lung Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Lung Disease pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 

 Reasons to buy 

 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for Lung Disease 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding Lung Disease pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Table of Contents 

 Introduction 6 

 Global Markets Direct Report Coverage 6 

 Lung Disease Overview 7 

 Therapeutics Development 8 

 Pipeline Products for Lung Disease - Overview 8 

 Pipeline Products for Lung Disease - Comparative Analysis 9 

 Lung Disease - Therapeutics under Development by Companies 10 

 Lung Disease - Therapeutics under Investigation by Universities/Institutes 12 

 Lung Disease - Pipeline Products Glance 13 

 Clinical Stage Products 13 

 Early Stage Products 14 

 Lung Disease - Products under Development by Companies 15 

 Lung Disease - Products under Investigation by Universities/Institutes 16 

 Lung Disease - Companies Involved in Therapeutics Development 17 

 Ablynx NV 17 

 Vectura Group plc 18 

 Pharmaxis Limited 19 

 AGI Therapeutics plc 20 

 Nostrum Pharmaceuticals, LLC 21 

 PharmaIN Corporation 22 

 Paranta Biosciences Limited 23 

 Serendex Pharmaceuticals A/S 24 

 Lung Disease - Therapeutics Assessment 25 

 Assessment by Monotherapy Products 25 

 Assessment by Target 26 

 Assessment by Mechanism of Action 28 

 Assessment by Route of Administration 30 

 Assessment by Molecule Type 32 

 Drug Profiles 34 

 cladribine - Drug Profile 34 

 Product Description 34 

 Mechanism of Action 34 

 R&D Progress 34 

 sargramostim - Drug Profile 35 

 Product Description 35 

 Mechanism of Action 35 

 R&D Progress 35 

 VR-461 - Drug Profile 36 

 Product Description 36 

 Mechanism of Action 36 

 R&D Progress 36 

 PXS-4206 - Drug Profile 37 

 Product Description 37 

 Mechanism of Action 37 

 R&D Progress 37 

 AGI-350 - Drug Profile 38 

 Product Description 38 

 Mechanism of Action 38 

 R&D Progress 38 

 dapsone - Drug Profile 39 

 Product Description 39 

 Mechanism of Action 39 

 R&D Progress 39 

 Retinoic Acid Receptor Agonists - Drug Profile 40 

 Product Description 40 

 Mechanism of Action 40 

 R&D Progress 40 

 Recombinant Human Follistatin - Drug Profile 41 

 Product Description 41 

 Mechanism of Action 41 

 R&D Progress 41 

 PGC-VIP - Drug Profile 42 

 Product Description 42 

 Mechanism of Action 42 

 R&D Progress 42 

 Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Lung And Liver Diseases - Drug Profile 43 

 Product Description 43 

 Mechanism of Action 43 

 R&D Progress 43 

 Nanobody 1 For Pulmonary Disease - Drug Profile 44 

 Product Description 44 

 Mechanism of Action 44 

 R&D Progress 44 

 Nanobody 2 For Pulmonary Disease - Drug Profile 45 

 Product Description 45 

 Mechanism of Action 45 

 R&D Progress 45 

 Ornithine-Substituted ADP-Ribosyl HNP-1 - Drug Profile 46 

 Product Description 46 

 Mechanism of Action 46 

 R&D Progress 46 

 Ornithine-HNP-1 - Drug Profile 47 

 Product Description 47 

 Mechanism of Action 47 

 R&D Progress 47 

 Lung Disease - Dormant Projects 48 

 Lung Disease - Product Development Milestones 49 

 Featured News & Press Releases 49 

 Oct 15, 2013: Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada 49 

 Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants 50 

 Mar 05, 2012: Medistem To Begin Clinical Trials Using ERC Stem Cells For Renal, Lung And Peripheral Artery Disease 51 

 Jan 02, 2012: Commonly Used Blood Pressure Drug Prevents Smoking-related Lung Damage In Mice 51 

 Appendix 54 

 Methodology 54 

 Coverage 54 

 Secondary Research 54 

 Primary Research 54 

 Expert Panel Validation 54 

 Contact Us 55 

 Disclaimer 55 

 

 List of Tables 

 Number of Products under Development for Lung Disease, H1 2014 8 

 Number of Products under Development for Lung Disease - Comparative Analysis, H1 2014 9 

 Number of Products under Development by Companies, H1 2014 11 

 Number of Products under Investigation by Universities/Institutes, H1 2014 12 

 Comparative Analysis by Clinical Stage Development, H1 2014 13 

 Comparative Analysis by Early Stage Development, H1 2014 14 

 Products under Development by Companies, H1 2014 15 

 Products under Investigation by Universities/Institutes, H1 2014 16 

 Lung Disease - Pipeline by Ablynx NV, H1 2014 17 

 Lung Disease - Pipeline by Vectura Group plc, H1 2014 18 

 Lung Disease - Pipeline by Pharmaxis Limited, H1 2014 19 

 Lung Disease - Pipeline by AGI Therapeutics plc, H1 2014 20 

 Lung Disease - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2014 21 

 Lung Disease - Pipeline by PharmaIN Corporation, H1 2014 22 

 Lung Disease - Pipeline by Paranta Biosciences Limited, H1 2014 23 

 Lung Disease - Pipeline by Serendex Pharmaceuticals A/S, H1 2014 24 

 Assessment by Monotherapy Products, H1 2014 25 

 Number of Products by Stage and Target, H1 2014 27 

 Number of Products by Stage and Mechanism of Action, H1 2014 29 

 Number of Products by Stage and Route of Administration, H1 2014 31 

 Number of Products by Stage and Molecule Type, H1 2014 33 

 Lung Disease - Dormant Projects, H1 2014 48 

 

 List of Figures 

 Number of Products under Development for Lung Disease, H1 2014 8 

 Number of Products under Development for Lung Disease - Comparative Analysis, H1 2014 9 

 Number of Products under Development by Companies, H1 2014 10 

 Number of Products under Investigation by Universities/Institutes, H1 2014 12 

 Comparative Analysis by Clinical Stage Development, H1 2014 13 

 Comparative Analysis by Early Stage Products, H1 2014 14 

 Assessment by Monotherapy Products, H1 2014 25 

 Number of Products by Top 10 Target, H1 2014 26 

 Number of Products by Stage and Top 10 Target, H1 2014 27 

 Number of Products by Top 10 Mechanism of Action, H1 2014 28 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29 

 Number of Products by Top 10 Route of Administration, H1 2014 30 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 31 

 Number of Products by Top 10 Molecule Type, H1 2014 32 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 33 

  

 Companies Mentioned 

 Ablynx NV 

 Vectura Group plc 

 Pharmaxis Limited 

 AGI Therapeutics plc 

 Nostrum Pharmaceuticals, LLC 

 PharmaIN Corporation 

 Paranta Biosciences Limited 

 Serendex Pharmaceuticals A/S